- Cardiometabolic-disease therapy addresses the four modifiable risk pillars — hyper-glycaemia, dyslipidaemia, hypertension and obesity — through drugs such as GLP-1/GIP receptor agonists, SGLT-2 inhibitors, statins/PCSK9 inhibitors and renin–angiotensin–aldosterone–system (RAAS) blockers. By normalising these parameters, the regimens cut major adverse cardiovascular events (MACE) and all-cause mortality, making them the cornerstone of long-term chronic-disease management for diabetes, heart failure and atherosclerotic CVD
- Escalating demand is fuelled by the twin pandemics of type-2 diabetes and obesity, population ageing, and the emergence of multi-benefit drugs (for instance, semaglutide, tirzepatide and coming triple-agonists) that tackle weight, glucose and cardiovascular risk in one shot
- North America dominates the cardiometabolic diseases market with a market share of 46% due to the early adoption of GLP-1s/PCSK9s, robust payer coverage and a deep clinical-trial pipeline led by U.S.-based majors
- Asia–Pacific is expected to be the fastest growing region in the cardiometabolic diseases market, due to large scale diabetes-hypertension screening, upgrade reimbursement and rapid urban-lifestyle shift
- ACE-inhibitor segment dominates the cardiometabolic diseases market with market share of 43.5% in 2024, reflecting its entrenched first-line status for blood-pressure and reno-cardio protection
